patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM Quick Tips

Small-Cap CEO Lessons - Is Your CEO Out Of Touch? ... Not Anymore

President's D.D.

4-17-12, Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial for the treatment of peripheral artery disease (PAD). read more

Stock Quote

Hub Leaders